Acurx Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 12, 2026 Conference Call and Provide Business Update

What happened

Acurx Pharmaceuticals said it will discuss its third quarter 2026 financial results on Thursday, November 12, 2026, at 8:00 a.m. ET, before U.S. financial markets open. CEO David P. Luci and CFO Robert G. Shawah will host the call and provide a business update.

Confirmed

Global impact / market context

Quarterly results and the business update give investors a scheduled look at the company's spending and progress. Acurx is funding a 20-patient pilot trial of its lead antibiotic candidate, so its cash position and trial progress matter to shareholders.

Analyst inference

Acurx is a late-stage biopharmaceutical company with no marketed product described in the article. Its lead candidate, ibezapolstat, targets C. difficile infection. Investors weigh trial enrollment and regulatory plans against the cost of developing the drug.

Analyst inference

What to watch

1. Acurx reported first patient enrollment in September 2026 in an open-label, single-arm pilot trial of 20 patients with multiply-recurrent C. difficile infection, meaning at least three prior episodes within the past 12 months. Confirmed
2. Acurx plans, if the trial succeeds, to pursue a Phase 3 regulatory strategy with just one registration trial in recurrent C. difficile infection under the FDA's Limited Population Pathway, which is a path for certain antibacterial drugs. Proposed
3. Listen for trial enrollment pace and cash available, meaning money on hand to fund operations, because slower enrollment or higher spending could change how long Acurx can fund its antibiotic development. Analyst inference

Evidence

• Original source link unavailable